3 news items
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL
16 May 24
registration-directed design; the potential of Nuvalent's pipeline programs, including NVL-655; Nuvalent's research and development programs
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL
9 May 24
.R&D Expenses: Research and development (R&D) expenses were
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL
8 Apr 24
and NVL-330; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug
- Prev
- 1
- Next